CAMBRIDGE, Mass.--(BUSINESS WIRE)--Third Rock Ventures, LLC today announced the formation of Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell ...

San Francisco, USA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Neoantigen Cancer Vaccine Market is rapidly emerging as one of the most transformative frontiers in modern oncology, reflecting the global ...

Researchers unveil a groundbreaking DNA vaccine that supercharges immunity and boosts survival in patients with aggressive breast cancer—could this be the future of personalized cancer treatment?

What are the challenges with developing neoantigen-based precision therapeutics and how can they be solved? Samantha Zaroff, Senior Technical Writer at GenScript (NJ, USA), discusses. What challenges ...

New York, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer vaccines.

Pancreatic ductal adenocarcinoma (PDAC) remains a highly aggressive and deadly disease with a poor prognosis. Devastating characteristics, including limited strategies for early detection and a fast ...

Various clinical trials are assessing the potential of neoantigen-based cancer vaccines. As researchers continue to determine approaches for improving the number of patients who can benefit from ...

The saga of cancer treatment is marked by a relentless pursuit of effectiveness against a disease characterized by complexity and adaptability. While immunotherapy has opened new frontiers, the ...

Cancer research today is rapidly evolving, exploring more modalities and personalized options to help patients. For many patients diagnosed with earlier stages of the disease, the potential for ...

A personalized cancer vaccine targeting neoantigens in high-risk renal cell carcinoma (RCC) demonstrates promising results, with no disease recurrence in any of the nine participants over a 40.2-month ...